Skip to main content

Suicide Risk

0
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Plus Therapeutics
1 program
EHSSA- An Efficient and Holistic/Heuristic Semi-structured Suicide Assessment ToolN/A1 trial
Active Trials
NCT04888533CompletedEst. Jan 2020
Alliance Pharmaceuticals
1 program
Treatment as usualN/A1 trial
Active Trials
NCT06564948Recruiting1,040Est. Sep 2027

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Alliance PharmaceuticalsTreatment as usual
Plus TherapeuticsEHSSA- An Efficient and Holistic/Heuristic Semi-structured Suicide Assessment Tool

Clinical Trials (2)

Total enrollment: 1,040 patients across 2 trials

Treatment for Individuals Interacting with the Criminal Justice System

Start: Feb 2025Est. completion: Sep 20271,040 patients
N/ARecruiting
NCT04888533Plus TherapeuticsEHSSA- An Efficient and Holistic/Heuristic Semi-structured Suicide Assessment Tool

Efficient, Holistic, Heuristic and Semi-structured Suicide Assessment Tool (EHSSA) - Very Accurate Prediction of Risk.

Start: Aug 2019Est. completion: Jan 2020
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 1,040 patients
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.